Reproductive Health Matters
Volume 13, Issue 26 , Pages 25-34 , November 2005

Medical Abortion: Issues of Choice and Acceptability

References 

  1. World Health Organization. In: Safe Abortion: Technical and Policy Guidance for Health Systems. Geneva: WHO; 2003;p. 28
  2. Royal College of Obstetricians and Gynaecologists. The Care of Women Requesting Induced Abortion. National Evidence-Based Clinical Guidelines. London: RCOG, September 2004. Summary at: 〈 www.rcog.org.uk/resources/Public/pdf/abortion_summary.pdf〉. Accessed 27 August 2005
  3. WHO Essential Medicines Library. At: http://mednet3.who.int/EMLib/DiseaseTreatments/MedicineDetails.aspx?MedIDName=443@mifepristone-misoprostol〉. Accessed 27 August 2005
  4. Bjorge L, et al. Early pregnancy termination with mifepristone and misoprostol in Norway. Acta Obstetrica Gynecologica Scandinavica. 2001;80(11):1056–1061
  5. Ashok PW, Kidd A, Flett GM, et al. A randomized comparison of medical abortion and surgical vacuum aspiration at 10–13 weeks gestation. Human Reproduction. 2002;17(1):92–98
  6. Clark S, et al. Is medical abortion acceptable to all American women?. Journal of American Medical Women's Association. 2000;55(3 Suppl):177–182
  7. Hemmerling A, Siedentopf F, Kentenich H. Emotional impact and acceptability of medical abortion with mifepristone: a German experience. Journal of Psychosomatic Obstetrics and Gynaecology. 2005;26(1):23–31
  8. Fiala C, Winikoff B, Helstrom L, et al. Acceptability of home-use of misoprostol in medical abortion. Contraception. 2004;70(5):387–392
  9. Abdel-Aziz E, Hassan IM, Al-Taher H. Assessment of women's satisfaction with medical termination of pregnancy. Journal of Obstetrics and Gynaecology. 2004;24(4):429–433
  10. Iversen OE, Midboe G, Johnsen SL, et al. [Medical abortion–the first Norwegian experiences]. Tidsskrift Nor Laegeforen 2003;Sep:123. [In Norwegian]
  11. Honkanen H, von Hertzen H. Users' perspectives on medical abortion in Finland. Contraception. 2002;65(6):419–423
  12. Jensen JT, et al. Acceptability of suction curettage and mifepristone abortion in the United States: a prospective comparison study. American Journal of Obstetrics and Gynecology. 2000;182(6):1292–1299
  13. Phelps RH, et al. Mifepristone abortion in minors. Contraception. 2001;64(6):339–343
  14. Steele C, Chiarotti S. With everything exposed: cruelty in post-abortion care in Rosario, Argentina. Reproductive Health Matters. 2004;12(24 Suppl.):39–46
  15. Ashok PW, Templeton A, Wagaarachchi PT, et al. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. BJOG. 2002;109(11):1281–1289
  16. Henderson JT, Hwang AC, Harper CC, et al. Safety of mifepristone abortions in clinical use. Contraception. 2005;72(3):175–178
  17. US Food and Drug Administration. FDA Alert for Health Professionals: Mifepristone, 22 July 2005. At: 〈 http://www.fda.gov/cder/drug/InfoSheets/HCP/MifepristoneHCP.pdf〉. Accessed 29 August 2005
  18. Winikoff B. Global overview of medical abortion. Presentation at Medical Abortion: An International Forum on Policies, Programmes and Services, 17–20 October 2004, Johannesburg.
  19. Say L, Kulier R, Gulmezoglu M, et al. Medical versus surgical methods for first trimester termination of pregnancy. Cochrane Database Systematic Reviews. 2005;25(1):CD003037
  20. See for example, Faucher P, Baunot N, Madelenat P. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients]. Gynecology, Obstetrics, Fertility 2005;33(4): 220–27. [In French]
  21. See for example, Hamoda H, Ashok PW, Flett GM, et al. Medical abortion at 9–13 weeks’ gestation: a review of 1076 consecutive cases. Contraception. 2005;71(5):327–32.
  22. Winikoff B, Ellertson C, Clark S. Analysis of failure in medical abortion. Contraception. 1996;54:323–327
  23. Urquhart D, Templeton A, Shinewi F, et al. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation; UK Multicentre Study—final results. Contraception. 1997;55:1–5
  24. Hamoda H, Ashok PW, Flett GM, et al. Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation. BJOG: An International Journal of Obstetrics and Gynaecology. 2004;111(9):996–1000
  25. Shannon CS, Winikoff B, Hausknecht R, et al. Multicenter trial of a simplified mifepristone medical abortion regimen. Obstetrics and Gynecology. 2005;105(2):345–351
  26. Ganatra B. Contrasts and common ground: the context of abortion in Asia. Presentation at Medical Abortion: An International Forum on Policies, Programmes and Services, 17–20 October 2004, Johannesburg.
  27. Ngoc NT, et al. Is home-based administration of prostaglandin safe and feasible for medical abortion? Results from a multisite study in Vietnam. BJOG: An International Journal of Obstetrics and Gynaecology. 2004;111(8):814–819
  28. Hajri S, Blum J, Gueddana N, et al. Expanding medical abortion in Tunisia: women's experiences from a multi-site expansion study. Contraception. 2004;70(6):487–491
  29. Hamoda H, Critchley HO, Paterson K, et al. The acceptability of home medical abortion to women in UK settings. BJOG: An International Journal of Obstetrics and Gynaecology. 2005;112(6):781–785
  30. Ashima T, Vinita A, Shalini R. Early medical abortion: a new regimen up to 49 days' gestation. Australia & New Zealand Journal of Obstetrics & Gynaecology. 2005;45(2):137–139
  31. Cullingworth L. A cost analysis of service provision of medical abortions in the public health sector at primary and secondary level. Presentation at Medical Abortion: An International Forum on Policies, Programmes and Services, 17–20 October 2004, Johannesburg.
  32. Ganatra B, Bygdeman M, Phan Bich Thuy , et al. From research to reality: the challenges of introducing medical abortion into service delivery in Vietnam. Reproductive Health Matters. 2004;12(24 Suppl):105–113
  33. Grimes DA, Smith MS, Witham AD. Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomised controlled trial. BJOG: An International Journal of Obstetrics and Gynaecology. 2004;111(2):148–153
  34. Fiala C, Swahn ML, Stephansson O, et al. The effect of non-steroidal anti-inflammatory drugs on medical abortion with mifeprisone and misoprostol at 13–22 weeks gestation. Human Reproduction 2005; August 11 (Abstract only, e-publication).
  35. Ashok PW, Templeton A, Wagaarachchi PT, et al. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception. 2004;69(1):51–58
  36. Espinoza H, Abuabara K, Ellertson C. Physicians' knowledge and opinions about medication abortion in four Latin American and Caribbean region countries. Contraception. 2004;70(2):127–133
  37. Joffe C, Yanow S. Advanced practice clinicians as abortion providers: current developments in the United States. Reproductive Health Matters. 2004;12(24 Suppl.):198–206

PII: S0968-8080(05)26204-3

doi: 10.1016/S0968-8080(05)26204-3

Reproductive Health Matters
Volume 13, Issue 26 , Pages 25-34 , November 2005

Article Tools